Literature DB >> 10805413

Evaluation of endothelium-protective effects of drugs in experimental models of endothelial damage.

V Kristová1, M Kriska, P Babál, M N Djibril, J Slámová, A Kurtansky.   

Abstract

Endothelium-protective properties of pharmacological agents may be assessed by using different experimental models of endothelial dysfunction or injury. The model of endothelial dysfunction induced by vessel perfusion with polymorphonuclear leukocytes (PMN) was used for evaluation of pentoxifylline (PTX) effects on vasoconstrictor responses to noradrenaline (NA) in the rabbit renal artery. Addition of PMN into the perfusion solution significantly increased the responses to NA at all doses. PTX administration (10(-5) mol x l(-1)) significantly diminished the constrictor responses to NA in vessels perfused with PMN+PTX when compared to the responses in PMN-perfused vessels (at dose 0.1 microg: 32.25 vs. 14.25, at dose 1 microg: 51 vs. 27.75 (p<0.01), at dose 10 microg 74.25 vs. 39.75 (p<0.05), all values expressed as median of perfusion pressure in mm Hg). The model of endothelial damage induced by repeated NA administration in 5 doses (10-50 microg of NA) was used for evaluation of the endothelium-protective effect of sulodexide (SLX). It was found that SLX (120 U/l) significantly decreased the number of desquamated endothelial cells (EC) compared to the control group (controls: 131.4+/-20.1 EC, +SLX: 83.3+/-13.8 EC, p<0.01). These results confirmed the favorable endothelium-protective effects of pentoxifylline and sulodexide in the two experimental models.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10805413

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  6 in total

1.  Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure.

Authors:  Ping Li; Lin-lin Ma; Ru-juan Xie; Yuan-sheng Xie; Ri-bao Wei; Min Yin; Jian-zhong Wang; Xiang-mei Chen
Journal:  Acta Pharmacol Sin       Date:  2012-05       Impact factor: 6.150

2.  Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy.

Authors:  Michele Rossini; Takashi Naito; Haichun Yang; Michael Freeman; Ellen Donnert; Li-Jun Ma; Stephen R Dunn; Kumar Sharma; Agnes B Fogo
Journal:  Nephrol Dial Transplant       Date:  2010-01-07       Impact factor: 5.992

3.  Sulodexide reduces senescence-related changes in human endothelial cells.

Authors:  Katarzyna Suminska-Jasinska; Alicja Polubinska; Marta Ciszewicz; Adam Mikstacki; Artur Antoniewicz; Andrzej Breborowicz
Journal:  Med Sci Monit       Date:  2011-04

4.  Trends in vascular pharmacology research in the Department of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University, Bratislava.

Authors:  Viera Kristová; Milan Kriška; Róbert Vojtko; Miriam Petrová; Silvia Líšková; Radoslav Villáris; Zoltán Varga; Martin Wawruch
Journal:  Interdiscip Toxicol       Date:  2011-03

5.  Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered.

Authors:  Antonio V Gaddi; Arrigo Fg Cicero; Giovanni Gambaro
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-07-06

6.  Effect of sulodexide in patients with non-proliferative diabetic retinopathy: diabetic retinopathy sulodexide study (DRESS).

Authors:  Ji Hun Song; Hee Seung Chin; Oh Woong Kwon; Su Jin Lim; Ha Kyoung Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-08-12       Impact factor: 3.117

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.